Clinical Trial Update: Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating lower dosing regimens of abiraterone (500 mg) in men with prostate cancer to identify the lowest recommended dose; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: University of Chicago | Conditions: Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Status: TERMINATED